Skip to content
GERICLINICS

Flashcards · Module 25

🚻 Bladder, Prostate & Pelvic Health (Urology & Gynecology)

4 of 4 cards published · read by the site’s author on 21 November 2026

Postmenopausal Vaginal Bleeding: Cancer until proven otherwise (The 4 mm stripe rule)

Needs clinical review

The Core Rule of Gynecology:

Any vaginal bleeding occurring ≥12 months after the menopause is postmenopausal bleeding and represents Endometrial Adenocarcinoma until proven otherwise!

Etiologies:

  • Endometrial atrophy (the most common cause)

  • Endometrial polyps

  • Endometrial Carcinoma: about 9% (pooled risk, 95% CI 8%–11%)

The Diagnostic Algorithm:

  1. Transvaginal Ultrasound (TVUS) plus endometrial sampling for most women (ACOG update, April 2026). Measure the endometrial stripe:

    • 🟢 Stripe ≤ 4 mm: ultrasound alone is enough only after a single episode, with the endometrium fully seen, no risk factors for endometrial cancer and no barrier to prompt re-evaluation.

    • 🔴 Stripe > 4 mm: premalignant and malignant lesions become more likely as the stripe thickens. Endometrial biopsy (Pipelle), the best-performing sampling technique for detecting cancer.

  2. If the endometrium cannot be fully seen on TVUS, ultrasound alone is not enough: sample the endometrium.

One-Liner: Postmenopausal bleeding must be evaluated for endometrial cancer; since ACOG's 2026 update most women have endometrial sampling as well as ultrasound, and a fully seen stripe ≤4 mm spares sampling only in low-risk women after a single episode.
Sources checked (5) · 18 November 2026

Note: An endometrial thickness of 4 mm or less has a negative predictive value above 99% for endometrial cancer. (ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding (2018))

Note: If blind endometrial sampling does not reveal hyperplasia or malignancy, hysteroscopy with dilation and curettage is warranted for persistent or recurrent bleeding. (ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding (2018))

Pelvic Organ Prolapse & Pessary Care: Silicone support and topical estrogen protection

Needs clinical review

What is Pelvic Organ Prolapse (POP)?

Herniation of pelvic structures into the vagina due to weakening of pelvic floor musculature and endopelvic fascia:

  • Cystocele (bladder prolapse into anterior wall)

  • Rectocele (rectum bulging into posterior wall)

  • Uterine / Apical prolapse (cervix/uterus descending toward introitus)

Conservative Management: Vaginal Pessaries

For women who would rather defer surgery, a pessary (ring, ring with support, Gellhorn; plastic or silicone) holds the prolapse back and relieves symptoms.

Two Pessary Care Rules:

  1. 🧼 Regular Removal & Cleaning: with clinic-based care, the pessary is removed, washed with mild soap and water, and checked at intervals of no more than 6 months. Neglected pessaries cause most complications: erosion and ulceration, and rarely impaction or vesicovaginal and rectovaginal fistulas.

  2. 🧴 Topical Vaginal Estrogen Cream (When Clinically Indicated): Postmenopausal vaginal mucosa is thin and friable. Consider topical vaginal estradiol cream (maintenance 1 g one to three times weekly per FDA label) where clinically indicated to restore the vaginal mucosa and minimize erosion or ulceration.

One-Liner: Vaginal pessaries relieve pelvic organ prolapse without surgery; they need regular removal, cleaning and checks (clinic follow-up at no more than 6 months) and topical vaginal estrogen where clinically indicated.
Sources checked (4) · 18 November 2026

Note: In a trial, cleaning every 6 months gave no more ulcers than every 3 months, though bacterial vaginosis was more common. (Updates in Pessary Care for Pelvic Organ Prolapse: A Narrative Review (2025))

Note: Pessary guidelines advise topical vaginal estrogen where appropriate to minimize adverse outcomes, and a 4-week pessary break with vaginal estrogen for worsening erosions. (Updates in Pessary Care for Pelvic Organ Prolapse: A Narrative Review (2025))

BPH Medications: Tamsulosin (Fast muscle relaxer) vs. Finasteride (Slow prostate shrinker)

Needs clinical review

The Two Drug Classes for Benign Prostatic Hyperplasia:

Drug ClassPrototypeMechanismSpeed of OnsetProstate Size ImpactSide Effects
Alpha-1 BlockersTamsulosin (Flomax), AlfuzosinRelaxes smooth muscle tone in the bladder neck and prostate capsuleFAST (relief within days to weeks)Zero effect (prostate remains same size)• Orthostatic hypotension & falls
• Dizziness
• Intraoperative Floppy Iris Syndrome (IFIS) 👁️
5-Alpha Reductase Inhibitors (5-ARIs)Finasteride (Proscar), DutasterideBlocks conversion of testosterone to DHT (dihydrotestosterone)SLOW (takes 6 to 12 months!)Shrinks prostate volume by about 18–28%• Decreased libido, erectile dysfunction
• Gynecomastia
• Halves serum PSA levels! 🚨

Two Critical Board Pearls:

  1. The Floppy Iris Warning: Warn any patient on Tamsulosin to tell their eye surgeon before cataract surgery; alpha-1 blockade causes iris billowing and pupillary constriction during surgery.

  2. The PSA Rule: after six months or more of finasteride, serum PSA falls by about half, so double the measured PSA before comparing it with normal ranges in untreated men.

One-Liner: Tamsulosin works fast by relaxing smooth muscle (watch for floppy iris and falls); Finasteride shrinks the prostate over 6–12 months and cuts measured PSA in half.
Sources checked (5) · 18 November 2026

Note: In a population cohort of men aged ≥66 years initiating tamsulosin, alfuzosin, or silodosin, alpha-antagonists were associated with increased risks of falling (OR 1.14) and hypotension (OR 1.80). (The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study (2015))

Note: Any confirmed increase in PSA from the lowest value while on finasteride may signal prostate cancer and should be evaluated, even if values remain within the normal range. (DailyMed - PROSCAR- finasteride tablet, film coated)

Late-Onset Hypogonadism (LOH): Diagnosing low testosterone and avoiding thick blood (hematocrit)

Needs clinical review

When is Low Testosterone Truly a Disease?

Do not test testosterone just because a 75-year-old feels tired!
Strict Diagnostic Criteria Require BOTH:

  1. Persistent Clinical Symptoms: above all the sexual ones: low sexual desire (libido), fewer morning erections, erectile dysfunction.

  2. Confirmed Biochemical Deficiency: At least two separate morning fasting Total Testosterone levels <300 ng/dL (about 10.4 nmol/L).

Do Not Start Testosterone With:

  • Prostate cancer or breast cancer

  • Palpable prostate nodule, or PSA >4 ng/mL, until a urologist has assessed it

  • Severe untreated sleep apnea

  • Uncontrolled congestive heart failure

  • Baseline Hematocrit >50%

The Safety Monitoring Rule:

Testosterone stimulates erythropoiesis (RBC production in bone marrow).

  • Recheck testosterone, hematocrit and PSA at 3–6 months, then review annually.

  • 🚨 HOLD OR ADJUST TESTOSTERONE if Hematocrit rises >54%! Erythrocytosis increases blood viscosity and thromboembolic risk (including deep vein thrombosis and pulmonary embolism).

One-Liner: Diagnose hypogonadism only with symptoms plus two morning fasting testosterone levels <300 ng/dL; hold or adjust therapy if hematocrit exceeds 54% to reduce thromboembolic risk.
Sources checked (3) · 18 November 2026

Note: Testosterone therapy improves libido (though it may be less effective for erectile dysfunction) and can have modest positive effects on bone strength and some measures of physical strength. (Testosterone replacement therapy and cardiovascular safety in older men: lessons from TRAVERSE and beyond (2026))

Note: The Endocrine Society guideline specifies fasting morning total testosterone confirmed on a repeat morning fasting sample, and free testosterone when total testosterone is near the lower limit or SHBG is altered. (Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018))

Note: In men at higher prostate cancer risk (such as African American men or those with an affected first-degree relative), the Endocrine Society threshold for urological evaluation before starting testosterone is PSA >3 ng/mL. (Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018))

Note: Some guidelines (such as AACE and ICSM) also apply a more conservative on-treatment hematocrit threshold of 50% alongside the standard 54% intervention cutoff. (Testosterone replacement therapy and cardiovascular safety in older men: lessons from TRAVERSE and beyond (2026))

Note: Postmarketing reports note venous thromboembolic events (DVT and PE) with testosterone gel; in the TRAVERSE outcomes study, testosterone gel demonstrated non-inferiority versus placebo for MACE (CV death, non-fatal MI, and non-fatal stroke). (DailyMed - ANDROGEL- testosterone gel)